11 research outputs found
Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial
© 2014 Laman et al. Artemisinin combination therapies (ACTs) with broad efficacy are needed where multiple Plasmodium species are transmitted, especially in children, who bear the brunt of infection in endemic areas. In Papua New Guinea (PNG), artemether-lumefantrine is the first-line treatment for uncomplicated malaria, but it has limited efficacy against P. vivax. Artemisinin-naphthoquine should have greater activity in vivax malaria because the elimination of naphthoquine is slower than that of lumefantrine. In this study, the efficacy, tolerability, and safety of these ACTs were assessed in PNG children aged 0.5–5 y.An open-label, randomized, parallel-group trial of artemether-lumefantrine (six doses over 3 d) and artemisinin-naphthoquine (three daily doses) was conducted between 28 March 2011 and 22 April 2013. Parasitologic outcomes were assessed without knowledge of treatment allocation. Primary endpoints were the 42-d P. falciparum PCR-corrected adequate clinical and parasitologic response (ACPR) and the P. vivax PCR-uncorrected 42-d ACPR. Non-inferiority and superiority designs were used for falciparum and vivax malaria, respectively. Because the artemisinin-naphthoquine regimen involved three doses rather than the manufacturer-specified single dose, the first 188 children underwent detailed safety monitoring. Of 2,542 febrile children screened, 267 were randomized, and 186 with falciparum and 47 with vivax malaria completed the 42-d follow-up. Both ACTs were safe and well tolerated. P. falciparum ACPRs were 97.8% and 100.0% in artemether-lumefantrine and artemisinin-naphthoquine-treated patients, respectively (difference 2.2% [95% CI -3.0% to 8.4%] versus -5.0% non-inferiority margin, p?=?0.24), and P. vivax ACPRs were 30.0% and 100.0%, respectively (difference 70.0% [95% CI 40.9%–87.2%], p<0.001). Limitations included the exclusion of 11% of randomized patients with sub-threshold parasitemias on confirmatory microscopy and direct observation of only morning artemether-lumefantrine dosing.Artemisinin-naphthoquine is non-inferior to artemether-lumefantrine in PNG children with falciparum malaria but has greater efficacy against vivax malaria, findings with implications in similar geo-epidemiologic settings within and beyond Oceania.Australian New Zealand Clinical Trials Registry ACTRN12610000913077.Please see later in the article for the Editors' Summary
Acquisition of antibodies against endothelial protein C receptor-binding domains of <i>Plasmodium falciparum</i> erythrocyte membrane protein 1 in children with severe malaria
BACKGROUND: Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) mediates parasite sequestration in postcapillary venules in P. falciparum malaria. PfEMP1 types can be classified based on their cysteine-rich interdomain region (CIDR) domains. Antibodies to different PfEMP1 types develop gradually after repeated infections as children age, and antibodies to specific CIDR types may confer protection. METHODS: Levels of immunoglobulin G to 35 recombinant CIDR domains were measured by means of Luminex assay in acute-stage (baseline) and convalescent-stage plasma samples from Papua New Guinean children with severe or uncomplicated malaria and in healthy age-matched community controls. RESULTS: At baseline, antibody levels were similar across the 3 groups. After infection, children with severe malaria had higher antibody levels than those with uncomplicated malaria against the endothelial protein C receptor (EPCR) binding CIDRα1 domains, and this difference was largely confined to older children. Antibodies to EPCR-binding domains increased from presentation to follow-up in severe malaria, but not in uncomplicated malaria. CONCLUSIONS: The acquisition of antibodies against EPCR-binding CIDRα1 domains of PfEMP1 after a severe malaria episode suggest that EPCR-binding PfEMP1 may have a role in the pathogenesis of severe malaria in Papua New Guinea
Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial
BACKGROUND: Artemisinin combination therapies (ACTs) with broad
efficacy are needed where multiple Plasmodium species are
transmitted, especially in children, who bear the brunt of
infection in endemic areas. In Papua New Guinea (PNG),
artemether-lumefantrine is the first-line treatment for
uncomplicated malaria, but it has limited efficacy against P.
vivax. Artemisinin-naphthoquine should have greater activity in
vivax malaria because the elimination of naphthoquine is slower
than that of lumefantrine. In this study, the efficacy,
tolerability, and safety of these ACTs were assessed in PNG
children aged 0.5-5 y. METHODS AND FINDINGS: An open-label,
randomized, parallel-group trial of artemether-lumefantrine (six
doses over 3 d) and artemisinin-naphthoquine (three daily doses)
was conducted between 28 March 2011 and 22 April 2013.
Parasitologic outcomes were assessed without knowledge of
treatment allocation. Primary endpoints were the 42-d P.
falciparum PCR-corrected adequate clinical and parasitologic
response (ACPR) and the P. vivax PCR-uncorrected 42-d ACPR.
Non-inferiority and superiority designs were used for falciparum
and vivax malaria, respectively. Because the
artemisinin-naphthoquine regimen involved three doses rather
than the manufacturer-specified single dose, the first 188
children underwent detailed safety monitoring. Of 2,542 febrile
children screened, 267 were randomized, and 186 with falciparum
and 47 with vivax malaria completed the 42-d follow-up. Both
ACTs were safe and well tolerated. P. falciparum ACPRs were
97.8% and 100.0% in artemether-lumefantrine and
artemisinin-naphthoquine-treated patients, respectively
(difference 2.2% [95% CI -3.0% to 8.4%] versus -5.0%
non-inferiority margin, p = 0.24), and P. vivax ACPRs were 30.0%
and 100.0%, respectively (difference 70.0% [95% CI 40.9%-87.2%],
p<0.001). Limitations included the exclusion of 11% of
randomized patients with sub-threshold parasitemias on
confirmatory microscopy and direct observation of only morning
artemether-lumefantrine dosing. CONCLUSIONS:
Artemisinin-naphthoquine is non-inferior to
artemether-lumefantrine in PNG children with falciparum malaria
but has greater efficacy against vivax malaria, findings with
implications in similar geo-epidemiologic settings within and
beyond Oceania. TRIAL REGISTRATION: Australian New Zealand
Clinical Trials Registry ACTRN12610000913077 Please see later in
the article for the Editors' Summary
Fever and parasite clearance times by <i>Plasmodium</i> species and allocated treatment.
<p>Data are number/total (percentage) or mean (95% confidence interval).</p><p>Fever and parasite clearance times by <i>Plasmodium</i> species and allocated treatment.</p
Kaplan-Meier plots showing percentages of patients positive for PCR-corrected <i>P. falciparum</i> and for PCR-uncorrected <i>P. vivax</i> after treatment.
<p>Data are for artemether-lumefantrine (solid lines) and artemisinin-naphthoquine (dashed lines). Numbers of children at risk at each time point are shown for artemether-lumefantrine (AL) and artemisinin-naphthoquine (AN). <i>p</i>-Values are for log-rank tests.</p
Incidence rate of main reported or observed signs and symptoms during the first 7 d of follow-up in randomized children, expressed as reports per 100 observations.
<p>Poisson regression with follow-up time as the exposure was used to derive incident rate ratios with artemether-lumefantrine as reference. Data on signs/symptoms from ten children were lost prior to database entry.</p><p>IRR, incident rate ratio.</p><p>Incidence rate of main reported or observed signs and symptoms during the first 7 d of follow-up in randomized children, expressed as reports per 100 observations.</p
Baseline characteristics of patients classified by <i>Plasmodium</i> species and allocated treatment.
<p>Data are percentage, mean ± standard deviation, median (interquartile range), or median [absolute range].</p><p>Baseline characteristics of patients classified by <i>Plasmodium</i> species and allocated treatment.</p
Demographic, clinical, and laboratory parameters as part of safety monitoring.
<p>IQR, interquartile range; SD, standard deviation.</p><p>Demographic, clinical, and laboratory parameters as part of safety monitoring.</p